NIH Study Keeps Synairgen’s Dream Of An Inhaled COVID-19 Therapy Alive
Two Readouts Expected In 2022
SNG001 has moved into a Phase III open label trial in which it must prove its non-inferiority against Regeneron's monoclonal antibody cocktail.
You may also be interested in...
Synairgen’s Hopes For Inhaled COVID-19 Therapy Dwindle
The company is running out of chances for its inhaled interferon therapy after a Phase III study failed to show benefits for hospitalized COVID-19 patients.
Merck’s Molnupiravir Set To Lead Forecast $6bn COVID-19 Oral Antiviral Market
Merck’s antiviral could play a big role, but only if it proves effective in broader settings, such as post-exposure prophylaxis.
Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage
Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.